Researchers at a Montreal institution have made significant strides in the management of severe bleeding, particularly for individuals with clotting disorders. Their innovative method, termed “click clotting”, aims to utilise a patient’s own blood—or donor blood—to create a more robust blood clot through a precise chemical reaction, thereby enhancing the speed and efficacy of bleeding control compared to existing methods.
A Breakthrough in Clotting Technology
Dr. Jianyu Li, a mechanical engineering professor at McGill University and one of the senior authors of the study, highlighted the urgent need for improved strategies to manage heavy bleeding, also known as haemorrhage. “The traditional methods have their limitations,” he remarked, emphasising the necessity for advancements in this critical area of healthcare.
This research initiative was spearheaded by Shuaibing Jiang, a postdoctoral associate affiliated with Mass General Brigham and Women’s Hospital at Harvard Medical School, during his doctoral studies at McGill. Collaborative efforts included contributions from experts at the University of British Columbia, the Medical College of Wisconsin, the University of Colorado Boulder, the University of Toronto, and the Versiti Blood Research Institute.
Addressing Existing Limitations
Previous attempts to create stronger blood clots involved the use of blood cells to generate chitosan, a substance that proved to be brittle and inconsistent in its clotting abilities. In contrast, the click clotting technique has shown promising results, allowing for clot formation within a mere 10 to 20 minutes. This rapid response time is crucial in emergency scenarios, such as inpatient care and wound management, where every second counts.
Dr. Li elaborated on the advantages of the new method, stating, “With a better clot, you can help to very quickly stop the bleeding. Additionally, the natural properties of blood promote regeneration.” He described the technology as potentially life-saving, capable of stopping severe bleeding almost instantaneously.
Testing and Efficacy
The study’s findings reveal that the newly developed synthetic blood clots are approximately ten times tougher than traditional ones, thereby enhancing their durability and effectiveness in the healing process. Initial tests conducted in vitro and on rodent models indicated remarkable outcomes, particularly in cases of liver injury, where healing and regeneration surpassed that of currently used clinical products.
According to the study’s release, there was also “minimal evidence” of immune reactivity, with no significant toxicity observed in major organs. However, while the results are encouraging, Dr. Li underscored that further research is necessary before the click clotting method can transition into clinical use.
The Road Ahead
Future studies must focus on larger animal models and ultimately human trials to ascertain the most effective applications for this technology, whether in trauma situations or various surgical environments. “With a proper engineering approach, we can empower this technology and, hopefully, assist more individuals in clinical and surgical settings,” Dr. Li stated.
Why it Matters
The implications of this research are profound. If successfully implemented in clinical practice, click clotting could revolutionise emergency medical care, drastically reducing the time required to control severe bleeding. This innovation not only has the potential to save lives but also to enhance recovery processes for patients with clotting disorders. As the healthcare community awaits further developments, the prospect of a more effective and rapid response to haemorrhage could mark a significant leap forward in trauma and surgical care.
